FDA DOING "GOOD JOB" AT MEETING USER FEE REVIEW TIME GOALS -- PhRMA's MOSSINGHOFF; 80% OF 1995 USER FEE BIOLOGICS GAINING APPROVALS WITHIN TIMEFRAME
FDA is continuing to make "significant progress in bringing down review times" and meeting goals set by the user fee act, Pharmaceutical Research & Manufacturers of America President Gerald Mossinghoff said at a Jan. 17 press briefing in Washington, D.C.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth